Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis.

A recent meta-analysis has reported that intensive-dose statin drug increases the risk of incident diabetes. However, doubling of the statin dose generates only a further 6% decrease in low-density lipoprotein cholesterol (LDL-c) on average. This study aimed to determine whether statin therapy with...

Full description

Bibliographic Details
Main Authors: Rongrong Cai, Yang Yuan, Yi Zhou, Wenqing Xia, Pin Wang, Haixia Sun, Yue Yang, Rong Huang, Shaohua Wang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4133238?pdf=render
id doaj-fa1374e8e82e41f4b89dbe3251b719d6
record_format Article
spelling doaj-fa1374e8e82e41f4b89dbe3251b719d62020-11-24T21:24:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e10492210.1371/journal.pone.0104922Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis.Rongrong CaiYang YuanYi ZhouWenqing XiaPin WangHaixia SunYue YangRong HuangShaohua WangA recent meta-analysis has reported that intensive-dose statin drug increases the risk of incident diabetes. However, doubling of the statin dose generates only a further 6% decrease in low-density lipoprotein cholesterol (LDL-c) on average. This study aimed to determine whether statin therapy with lower intensive-target LDL-c level contributes to higher risk of new-onset diabetes.Medline, Embase, and the Cochrane Central Register of Controlled Trials were searched for randomized controlled endpoint trials of statins conducted from 1966 to 2012. We included trials with more than 1000 participants who were followed up for at least 2 years. The included trials were stratified by the target LDL-c level. I2 statistic was used to measure heterogeneity between trials. We further calculated risk estimates with random-effect meta-analysis. Meta-regression was used to identify the potential risk factors of statin-induced diabetes.Fourteen trials with a total of 95 102 non-diabetic participants were included. The risks elevated by 33% [odds ratio (OR)  = 1.33; 95% confidence interval (CI) 1.14-1.56; I(2) = 7.7%] and 16% (OR = 1.16; 95% CI 1.06-1.28; I(2)= 0.0%) when the intensified target LDL-c levels were ≤ 1.8 mmol/L and 1.8-2.59 mmol/L, respectively. The risk of incident diabetes did not increase when the target LDL-c level was ≥ 2.59 mmol/L. Apart from age, female, and baseline level of total cholesterol, meta-regression analysis showed that the target and baseline levels of LDL-c and relative LDL-c reduction were predictors of statin-induced diabetes.A lower intensified target LDL-c level of statin therapy resulted in a higher risk of incident diabetes.http://europepmc.org/articles/PMC4133238?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Rongrong Cai
Yang Yuan
Yi Zhou
Wenqing Xia
Pin Wang
Haixia Sun
Yue Yang
Rong Huang
Shaohua Wang
spellingShingle Rongrong Cai
Yang Yuan
Yi Zhou
Wenqing Xia
Pin Wang
Haixia Sun
Yue Yang
Rong Huang
Shaohua Wang
Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis.
PLoS ONE
author_facet Rongrong Cai
Yang Yuan
Yi Zhou
Wenqing Xia
Pin Wang
Haixia Sun
Yue Yang
Rong Huang
Shaohua Wang
author_sort Rongrong Cai
title Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis.
title_short Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis.
title_full Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis.
title_fullStr Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis.
title_full_unstemmed Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis.
title_sort lower intensified target ldl-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description A recent meta-analysis has reported that intensive-dose statin drug increases the risk of incident diabetes. However, doubling of the statin dose generates only a further 6% decrease in low-density lipoprotein cholesterol (LDL-c) on average. This study aimed to determine whether statin therapy with lower intensive-target LDL-c level contributes to higher risk of new-onset diabetes.Medline, Embase, and the Cochrane Central Register of Controlled Trials were searched for randomized controlled endpoint trials of statins conducted from 1966 to 2012. We included trials with more than 1000 participants who were followed up for at least 2 years. The included trials were stratified by the target LDL-c level. I2 statistic was used to measure heterogeneity between trials. We further calculated risk estimates with random-effect meta-analysis. Meta-regression was used to identify the potential risk factors of statin-induced diabetes.Fourteen trials with a total of 95 102 non-diabetic participants were included. The risks elevated by 33% [odds ratio (OR)  = 1.33; 95% confidence interval (CI) 1.14-1.56; I(2) = 7.7%] and 16% (OR = 1.16; 95% CI 1.06-1.28; I(2)= 0.0%) when the intensified target LDL-c levels were ≤ 1.8 mmol/L and 1.8-2.59 mmol/L, respectively. The risk of incident diabetes did not increase when the target LDL-c level was ≥ 2.59 mmol/L. Apart from age, female, and baseline level of total cholesterol, meta-regression analysis showed that the target and baseline levels of LDL-c and relative LDL-c reduction were predictors of statin-induced diabetes.A lower intensified target LDL-c level of statin therapy resulted in a higher risk of incident diabetes.
url http://europepmc.org/articles/PMC4133238?pdf=render
work_keys_str_mv AT rongrongcai lowerintensifiedtargetldlclevelofstatintherapyresultsinahigherriskofincidentdiabetesametaanalysis
AT yangyuan lowerintensifiedtargetldlclevelofstatintherapyresultsinahigherriskofincidentdiabetesametaanalysis
AT yizhou lowerintensifiedtargetldlclevelofstatintherapyresultsinahigherriskofincidentdiabetesametaanalysis
AT wenqingxia lowerintensifiedtargetldlclevelofstatintherapyresultsinahigherriskofincidentdiabetesametaanalysis
AT pinwang lowerintensifiedtargetldlclevelofstatintherapyresultsinahigherriskofincidentdiabetesametaanalysis
AT haixiasun lowerintensifiedtargetldlclevelofstatintherapyresultsinahigherriskofincidentdiabetesametaanalysis
AT yueyang lowerintensifiedtargetldlclevelofstatintherapyresultsinahigherriskofincidentdiabetesametaanalysis
AT ronghuang lowerintensifiedtargetldlclevelofstatintherapyresultsinahigherriskofincidentdiabetesametaanalysis
AT shaohuawang lowerintensifiedtargetldlclevelofstatintherapyresultsinahigherriskofincidentdiabetesametaanalysis
_version_ 1725989478526353408